About Qbic Venture Partners
Qbic Venture Partners offers products and services including Venture Capital Investment and Portfolio Management.
- SectorsHealthcareTechnology
- Email••••••••
- Social LinkedIn
- Legal Name Qbic Venture Partners
Products & Services of Qbic Venture Partners
Qbic Venture Partners offers a comprehensive portfolio of products and services, including Venture Capital Investment and Portfolio Management.
Funding is provided for early-stage startups emerging from university research
A portfolio of innovative companies is managed to foster sustainable business development
People of Qbic Venture Partners
4 people are tracked at Qbic Venture Partners (4 in leadership).
| Name | Role | Group |
|---|---|---|
Cedric van Nevel | Partner | Leadership |
Steven Leuridan | Partner | Leadership |
Sofie Baeten | CEO And Co-founder Qbic III | Leadership |
Martin de Prycker | Managing Partner | Leadership |
Complete people profiles for Qbic Venture Partners
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Latest news on Qbic Venture Partners
Complete news archive for Qbic Venture Partners
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Qbic Venture Partners
10 companies that operate in the same segment as Qbic Venture Partners (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 300 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Qbic Venture Partners
Qbic Venture Partners is established as an inter-university venture capital fund that emphasizes the transformation of technological breakthroughs into sustainable businesses. Investments are directed towards sectors like biotech and deeptech, supporting spin-offs from knowledge partners. The fund has facilitated job creation exceeding 350 positions and aims to benefit over 500 million patients while advancing 12 Sustainable Development Goals, with backing from European Union funding. This approach is recognized for its role in promoting innovation and ethical practices.
Qbic Venture Partners offers Venture Capital Investment and Portfolio Management.
Qbic Venture Partners operates through Qbic Venture Partners.